Ratos owns 95% of the capital and votes in Biolin Scientific after the extended acceptance period

2011-01-14

This information is disclosed in accordance with the Securites Markets Act and
NASDAQ OMX Stockholm's rules regarding public offers on the stock market.

This press release may not be distributed, directly or indirectly, in or into,
Australia, Canada, Japan, New Zealand, South Africa, Switzerland or the United
States of America. The Offer is not being made to (and acceptances will not be
accepted from) persons in those countries or in any other country where the
making of the Offer, the distribution of this press release or acceptance of the
Offer requires further offer documents, filings or other measures in addition to
those required by Swedish law.
Ratos owns a total of 25 264 243 shares and convertibles, corresponding to
95.05% of all shares and votes in Biolin Scientific following the end of the
extended acceptance period. Settlement in respect of shareholders that accepted
the offer during the extended acceptance period is expected to commence on 19
January 2011. The acceptance period is further extended until 24 February 2011.
Based on the final review of acceptances received during the extended acceptance
period, which ended on 12 January 2011, an additional 1 218 761 shares and
convertibles, corresponding to 4.59% of all shares and votes in Biolin
Scientific, have been tendered in the offer. This means that the offer has been
accepted by owners of a total of 24 642 835 shares and convertibles,
corresponding to 92.71% of the capital and votes in Biolin Scientific. Together
with 621 408 shares, corresponding to 2.34% of the capital and votes, acquired
outside the offer on NASDAQ OMX at a price of SEK 11.50 per share since 30
December 2010, Ratos now owns 25 264 243 shares and convertibles in Biolin
Scientific, corresponding to 95.05% of all capital and votes (after full
dilution). Consequently, Ratos has through the acquisitions of shares on NASDAQ
OMX reached an ownership above 90% (after full dilution) excluding the shares
tendered in the extended acceptance period.
To enable participation in the offer by those shareholders who have not yet
accepted the offer, the acceptance period is extended once more until 24
February 2011 at 17:00 CET. For those who accept the offer during this extra
extension of the acceptance period, settlement is expected to commence on 3
March 2011.
Since Ratos holds more than 90% of the capital and votes in Biolin Scientific,
Ratos intends shortly to initiate compulsory acquisition of the remaining shares
in Biolin Scientific and to promote a delisting of Biolin Scientific`s shares
from NASDAQ OMX Stockholm.
For further information, please contact:
Arne Karlsson, CEO, +46 70 379 79 79
Emma Rheborg, Head of Corporate Communications & IR, +46 8 700 17 20
Financial calendar from Ratos:
Year-end report 2010                    17 February 2011
Annual General Meeting 2011             5 April 2011
Interim Report January - March 2011     5 May 2011
Interim Report January - June 2011      19 August 2011
Interim Report January - September 2011 9 November 2011

Ratos is a private equity conglomerate. The company`s mission is to maximise
shareholder value over time through the professional, active and responsible
exercise of its ownership role in primarily medium to large unlisted Nordic
companies. Ratos`s holdings include AH Industries, Anticimex, Arcus Gruppen,
Biolin Scientific, Bisnode, Contex, DIAB, EuroMaint, GS-Hydro, Hafa Bathroom
Group, HL Display, Inwido, Jøtul, KVD Kvarndammen, Lindab, Medisize, Mobile
Climate Control, SB Seating, Stofa, Superfos and Other holdings. Ratos is listed
on NASDAQ OMX Stockholm and market capitalisation amounts to approximately SEK
42 billion.